Connect Biopharma (NASDAQ:CNTB – Get Free Report) announced its earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13), Zacks reports.
Connect Biopharma Price Performance
NASDAQ CNTB opened at $0.58 on Wednesday. The company has a market capitalization of $36.45 million, a PE ratio of -0.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37. The business’s fifty day moving average is $0.99 and its 200 day moving average is $2.09. Connect Biopharma has a fifty-two week low of $0.55 and a fifty-two week high of $3.82.
Analyst Upgrades and Downgrades
Several brokerages recently commented on CNTB. Leerink Partners assumed coverage on Connect Biopharma in a report on Monday, October 12th. They issued an “outperform” rating and a $4.00 price objective for the company. Wall Street Zen downgraded Connect Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Canaccord Genuity Group reissued a “buy” rating on shares of Connect Biopharma in a report on Tuesday. Oppenheimer dropped their target price on Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 22nd. Finally, Weiss Ratings downgraded Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Connect Biopharma presently has an average rating of “Moderate Buy” and an average price target of $5.88.
Check Out Our Latest Stock Report on Connect Biopharma
Connect Biopharma Company Profile
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
Further Reading
- Five stocks we like better than Connect Biopharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
